As emphasized by recent publications from the Heidelberg neuropathology group—key contributors to the 2021 WHO CNS tumor classification (Louis et al. 2021)—meningiomas demonstrate a broad spectrum of genetic alterations (e.g., NF2 inactivation, MEG3 and NDRG2 loss, Wnt/β-catenin and Hedgehog pathway involvement) and epigenetic changes. The gene discussed is NF2; the disease is meningioma.